Durvalumab in DLBCL After Autologous Transplant

Sponsor
Insel Gruppe AG, University Hospital Bern
Study ID
NCT03241017
Phase
PHASE2
Status
Withdrawn

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Immunotherapy with Durvalumab after ASCT

Study Details

The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.

Key Dates

Start date
Oct 31, 2017
Status verified
Apr 2018
Primary completion
Oct 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab
    Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).

Primary Outcome Measure

Progression-free survival [ Time Frame: 24 months ]

Related Studies